Discover
DYN
Dyne Therapeutics, Inc.
23.83
1 x 21.74
1 x 22.50
bid
ask
+
0.38
1.62%
100 @ 07:55 AM
21.52 -2.31 (9.69%)
| Ytd | 21.83% | |
| 1y | 158.74% |
23.18
day range
24.23
6.36
52 week range
47.45
| Open | 23.36 | Prev Close | 23.45 | Low | 23.18 | High | 24.23 | Mkt Cap | 3.94B |
| Vol | 1.37M | Avg Vol | 1.83M | EPS | -3.22 | P/E | N/A | Forward P/E | -8.10 |
| Beta | 1.06 | Short Ratio | 14.55 | Inst. Own | 115.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-27 | 50-d Avg | 19.91 | 200-d Avg | 18.66 | 1yr Est | 38.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-07-27 | 2026-06 | -0.74 | N/A | N/A | N/A |
| 2026-05-11 | 2026-03 | -0.77 | -0.73 | 0.04 | 5.48% |
| 2026-03-02 | 2025-12 | -0.74 | -0.76 | -0.02 | -2.70% |
| 2025-11-05 | 2025-09 | -0.81 | -0.76 | 0.05 | 6.17% |
| 2025-07-28 | 2025-06 | -0.99 | -0.97 | 0.02 | 2.02% |
| 2025-05-08 | 2025-03 | -0.88 | -1.05 | -0.17 | -19.32% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-26 | TD Cowen | Upgrade | Buy | |
| 2026-05-15 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-05-13 | Bernstein | Upgrade | Market Perform | Market Perform |
| 2026-03-09 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-03-03 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-03-03 | Chardan Capital | Upgrade | Buy | Buy |
Profile
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-03-10 | BESKROVNAYA OXANA | Officer | 195.84K | Sale |
| 2026-06-15 | COX JOHN | Chief Executive Officer | 440.15K | Sale |
| 2024-08-18 | FARWELL WILDON | Officer | 143.22K | Sale |
| 2026-06-15 | FRIEDL-NADERER JOHANNA | Officer | 154.21K | Sale |
| 2024-09-17 | HIGH SUSANNA GATTI | Chief Operating Officer | 131.64K | Sale |
| 2026-06-15 | KERR DOUGLAS | Officer | 169.16K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Investment Management,Inc. | 30.79M | 0.00 | 18.62% |
| 2026-03-30 | HHG PLC | 13.65M | 0.00 | 8.26% |
| 2026-03-30 | BlackRock Inc | 11.70M | 0.00 | 7.08% |
| 2025-12-30 | Vanguard Group Inc | 11.22M | 0.00 | 6.78% |
| 2026-03-30 | Atlas Venture Life Science Advisors, LLC | 9.13M | 0.00 | 5.52% |
| 2026-03-30 | FMR Inc | 8.91M | 0.00 | 5.39% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price US Small-Cap Core Equity | 7.01M | 0.00 | 4.24% |
| 2026-04-29 | T. Rowe Price Small-Cap Stock | 7.01M | 0.00 | 4.24% |
| 2026-04-29 | Vanguard Total Stock Mkt Idx Inv | 4.71M | 0.00 | 2.85% |
| 2026-04-29 | T. Rowe Price Small-Cap Value | 4.62M | 0.00 | 2.80% |
| 2026-04-29 | T. Rowe Price Instl Small-Cap Stock | 3.81M | 0.00 | 2.30% |
| 2026-05-30 | State Street® SPDR® S&P® Biotech ETF | 3.81M | 0.00 | 2.30% |